Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q3 FY25 results · Oct–Dec 2024
Emcure Pharmaceuticals reported revenue from operations of ₹1,962.63 crore and net profit of ₹156.09 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,962.63 | — | — | 2,001.98 | −2.0% |
| Other income | 3.90 | — | — | 35.65 | −89.1% |
| Total income | 1,966.53 | — | — | 2,037.64 | −3.5% |
| Profit before tax | 229.92 | — | — | 273.41 | −15.9% |
| Net profit for the period | 156.09 | — | — | 201.55 | −22.6% |
| Attributable to shareholders of the company | 153.72 | — | — | 194.57 | −21.0% |
| EPS, basic (₹) | 8.12 | — | — | 10.33 | −21.4% |
| Net margin (%) | 8.0 | — | 10.1 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,028.81 | — | — | 1,104.63 | −6.9% |
| Other income | 19.41 | — | — | 54.93 | −64.7% |
| Total income | 1,048.22 | — | — | 1,159.56 | −9.6% |
| Profit before tax | 67.25 | — | — | 119.36 | −43.7% |
| Net profit for the period | 50.20 | — | — | 86.92 | −42.2% |
| EPS, basic (₹) | 2.65 | — | — | 4.62 | −42.6% |
| Net margin (%) | 4.9 | — | 7.9 |
Consolidated
- Filed with BSE
- 06 Feb 2025, 15:30 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2025, 15:30 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE